BIOGEN INC

20 February, 2025

Biogen Partners with Stoke Therapeutics to Develop Zorevunersen for Dravet Syndrome, Investing Up to $550 Million

Biogen Inc. is making significant strides in its investment and development pipeline with the recent partnership with Stoke Therapeutics focused on zorevunersen, a promising drug candidate aimed at tr...
Read More

18 February, 2025

Biogen's Stock Plummets Over 5% as 2025 Earnings Forecast Falls Short of Expectations Amidst MS Sales Decline and Market Volatility

Biogen's stock has taken a hit, dropping over 5% following a disappointing forecast for 2025 adjusted earnings per share (EPS). The company anticipates EPS between $15.25 and $16.25, with the midpoint...
Read More

17 February, 2025

Biogen's Stock Plummets Over 5% as 2025 Earnings Forecast Falls Short of Expectations Amidst MS Sales Decline and Market Volatility

Biogen's stock has taken a hit, dropping over 5% following a disappointing forecast for 2025 adjusted earnings per share (EPS). The company anticipates EPS between $15.25 and $16.25, with the midpoint...
Read More

16 February, 2025

Biogen Awaits European Approval for Alzheimer's Drug Leqembi Amid Reassessment and Growing Sales Potential

Biogen, in collaboration with Eisai, is currently awaiting a crucial decision from the European Commission regarding the marketing approval of its Alzheimer's drug, Leqembi (lecanemab), aimed at treat...
Read More